Kinoxis Therapeutics
Kinoxis Therapeutics is a private, Australian-based, clinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological…
Overview
Kinoxis Therapeutics is a private, Australian-based, clinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders.
Kinoxis’ lead candidate (KNX100) is being developed treatment of agitation and aggression in dementia patients, and for the treatment of substance use disorders. KNX100 has an extensive pre-clinical data package consisting of several cross-species animal efficacy models validated across multiple institutions such as NIH/NIDA. This includes animal efficacy models in agitation and aggression in Alzheimer’s disease and substance use disorder models of alcohol, opioid, and methamphetamine. KNX100 has a novel mechanism of action, acting via disease relevant pharmacological, molecular and neural interactions.
Kinoxis has successfully completed a Phase 1 clinical study for KNX100 under a US IND and along with an extensive pre-clinical data package, are planning to initiate multiple Phase 2 clinical studies in agitation and aggression in dementia, opioid use disorder, alcohol use disorder and stimulant use disorder. This multifaceted potential sets KNX100 apart as a uniquely innovative and impactful candidate in the development of effective treatments in substance use disorders and social dysfunction in neurological and psychiatric disorders.
Additionally, Kinoxis are developing several other promising first-in-class, novel small molecules that target the brain oxytocin system. In May 2023, Kinoxis entered into a strategic partnership and licensing agreement with Boehringer Ingelheim worth up to US$181 million. This partnership works toward unlocking the therapeutic potential of targeting the brain oxytocin system to treat disrupted social behavior.
Delegates
